Chemical Structure : VVD-699
Catalog No.: PC-23785Not For Human Use, Lab Use Only.
VVD-699 is a specific, covalent inhibitor of RAS binding domain of PI3Kα (p110α RBD), disrupts the RAS-p110α interaction, binds covalently to Cys242 in p110α RBD and blocks the ability of RAS to activate PI3K activity.
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
VVD-699 is a specific, covalent inhibitor of RAS binding domain of PI3Kα (p110α RBD), disrupts the RAS-p110α interaction, binds covalently to Cys242 in p110α RBD and blocks the ability of RAS to activate PI3K activity.
VVD-699 shows no impact on p110α lipid kinase activity in biochemical assays.
VVD-699 inhibited pAKT in KRASG12S A549 cells, and this effect was lost in isogenic p110α C242S knock-in A549 cells, blocked downstream pathway activation across a wide range of cancer relevant RAS and p110α mutations.
VVD-699 inhibits HER2 activity through an H/K/N-RAS independent mechanism in KRAS hyperactive cell lines.
VVD-699 (100 mg/kg, oral) inhibits tumor growth without impacting glucose homeostasis in mice bearing FaDu xenografts (KRASamp), sensitizes tumors to KRASG12C Inhibition.
M.Wt | 573.09 | |
Formula | C25H30ClFN2O6S2 | |
Appearance | Solid | |
Storage |
|
|
Solubility |
10 mM in DMSO |
1. Klebba JE, et al. bioRxiv [Preprint]. 2024 Dec 20:2024.12.17.629001.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright